These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21348641)

  • 21. Assessment of TP53 mutations in benign and malignant salivary gland neoplasms.
    Gomes CC; Diniz MG; Orsine LA; Duarte AP; Fonseca-Silva T; Conn BI; De Marco L; Pereira CM; Gomez RS
    PLoS One; 2012; 7(7):e41261. PubMed ID: 22829934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract.
    Furihata M; Takeuchi T; Matsumoto M; Kurabayashi A; Ohtsuki Y; Terao N; Kuwahara M; Shuin T
    Clin Cancer Res; 2002 May; 8(5):1192-5. PubMed ID: 12006537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TP53 codon 72 polymorphism in radiation-associated human papillary thyroid cancer.
    Rogounovitch TI; Saenko VA; Ashizawa K; Sedliarou IA; Namba H; Abrosimov AY; Lushnikov EF; Roumiantsev PO; Konova MV; Petoukhova NS; Tchebotareva IV; Ivanov VK; Chekin SY; Bogdanova TI; Tronko MD; Tsyb AF; Thomas GA; Yamashita S
    Oncol Rep; 2006 Apr; 15(4):949-56. PubMed ID: 16525684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of p53 protein is common in premalignant head and neck lesions.
    Pavelic ZP; Li YQ; Stambrook PJ; McDonald JS; Munck-Wikland E; Pavelic K; Dacic S; Danilovic Z; Pavelic L; Mugge RE
    Anticancer Res; 1994; 14(5B):2259-66. PubMed ID: 7840533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The spectrum of TP53 mutations in bladder carcinoma.
    Williamson MP; Elder PA; Knowles MA
    Genes Chromosomes Cancer; 1994 Feb; 9(2):108-18. PubMed ID: 7513540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Associations of TP53 mutations, codon 72 polymorphism and human papillomavirus in head and neck squamous cell carcinoma patients.
    Shi Q; Xiao K; Wei W; Zhang BY; Chen C; Xu Y; Chen LN; Song YT; Ma X; Zhang NS; Dong XP
    Oncol Rep; 2013 Dec; 30(6):2811-9. PubMed ID: 24064928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequent inactivation of the TP53 gene in esophageal squamous cell carcinoma from a high-risk population in China.
    Hu N; Huang J; Emmert-Buck MR; Tang ZZ; Roth MJ; Wang C; Dawsey SM; Li G; Li WJ; Wang QH; Han XY; Ding T; Giffen C; Goldstein AM; Taylor PR
    Clin Cancer Res; 2001 Apr; 7(4):883-91. PubMed ID: 11309337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas.
    Langerød A; Bukholm IR; Bregård A; Lønning PE; Andersen TI; Rognum TO; Meling GI; Lothe RA; Børresen-Dale AL
    Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1684-8. PubMed ID: 12496062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH.
    Forslund A; Kressner U; Lönnroth C; Andersson M; Lindmark G; Lundholm K
    Int J Oncol; 2002 Aug; 21(2):409-15. PubMed ID: 12118339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
    de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
    Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TP53 genetic alterations in head-and-neck carcinomas from Brazil.
    Nagai MA; Miracca EC; Yamamoto L; Moura RP; Simpson AJ; Kowalski LP; Brentani RR
    Int J Cancer; 1998 Mar; 76(1):13-8. PubMed ID: 9533755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
    Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
    Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel mutation of STK11/LKB1 gene leads to the loss of cell growth inhibition in head and neck squamous cell carcinoma.
    Qiu W; Schönleben F; Thaker HM; Goggins M; Su GH
    Oncogene; 2006 May; 25(20):2937-42. PubMed ID: 16407837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequent mutations in TP53 and CDKN2A found by next-generation sequencing of head and neck cancer cell lines.
    Nichols AC; Yoo J; Palma DA; Fung K; Franklin JH; Koropatnick J; Mymryk JS; Batada NN; Barrett JW
    Arch Otolaryngol Head Neck Surg; 2012 Aug; 138(8):732-9. PubMed ID: 22911296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
    de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
    Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers.
    Gunduz M; Ouchida M; Fukushima K; Ito S; Jitsumori Y; Nakashima T; Nagai N; Nishizaki K; Shimizu K
    Oncogene; 2002 Jun; 21(28):4462-70. PubMed ID: 12080476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High resolution melting for mutation scanning of TP53 exons 5-8.
    Krypuy M; Ahmed AA; Etemadmoghadam D; Hyland SJ; ; DeFazio A; Fox SB; Brenton JD; Bowtell DD; Dobrovic A
    BMC Cancer; 2007 Aug; 7():168. PubMed ID: 17764544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer.
    Kyndi M; Alsner J; Hansen LL; Sørensen FB; Overgaard J
    Acta Oncol; 2006; 45(5):602-9. PubMed ID: 16864176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer.
    Schneider-Stock R; Mawrin C; Motsch C; Boltze C; Peters B; Hartig R; Buhtz P; Giers A; Rohrbeck A; Freigang B; Roessner A
    Am J Pathol; 2004 Apr; 164(4):1233-41. PubMed ID: 15039212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.